Constructing rendering of a brand new, state-of-the-art science and innovation center at Amgen’s global headquarters in Thousand Oaks, California.
Courtesy: Amgen
Amgen on Tuesday said it can spend greater than $600 million to construct a brand new research and development facility at its headquarters in Thousand Oaks, California, the newest in a string of recent U.S. investments by the pharmaceutical industry.Â
Drugmakers have been scrambling to spice up their presence within the U.S. as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country. Trump has said those levies will incentivize firms to re-shore production at a time when domestic drug manufacturing has shrunk dramatically over the past decade.Â
In a release, Amgen said construction of the ability will begin within the third quarter of this yr and can create a whole lot of U.S. jobs.Â
Notably, the ability just isn’t a producing plant, but it can allow researchers, engineers and scientists to collaborate on finding next-generation drugs for patients with “probably the most serious diseases,” in response to the corporate. Amgen said the constructing features “advanced automation and digital capabilities,” which can give scientists the crucial tools for that research and development.Â
“At Amgen, we’re continuing to speculate in the long run of American science and innovation,” CEO Bob Bradway said in the discharge. “The middle will empower our scientists with the tools and collaborative environment they should shape the subsequent era of scientific discovery and advance medicines that improve human health.”
Amgen said that for the reason that passage of the Tax Cuts and Jobs Act of 2017, it has invested almost $5 billion in direct U.S. capital expenditures. In April, the corporate announced a $900 million expansion of its Ohio biotech manufacturing facility. In December, the drugmaker announced it will spend $1 billion to construct a second drug substance plant in Holly Springs, North Carolina.
Those investments come after the U.S. Food and Drug Administration in August launched a program that goals to make it easier for firms to establish latest drug manufacturing plants within the U.S. The White House estimates it could currently take five to 10 years to construct latest manufacturing capability for pharmaceuticals, which it previously called “unacceptable from a national-security standpoint.”
